Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial of LNK01004 Ointment for Vitiligo
The randomized, double-blind study will assess the ointment’s efficacy and safety in adults with vitiligo as Lynk advances its dermatology pipeline.
- On July 9, Lynk Pharmaceuticals announced the first patient was dosed on June 30 in a Phase II clinical trial evaluating LNK01004 ointment for vitiligo treatment.
- Designed as a soft pan-JAK inhibitor, LNK01004 features a skin-restricted molecular structure minimizing systemic exposure while maintaining potent inhibitory activity to balance efficacy and safety.
- The randomized, double-blind trial is jointly led by Professor Jianzhong Zhang and Professor Cheng Zhou from the Department of Dermatology at Peking University People's Hospital across multiple centers.
- Dr. Henry Wu noted that vitiligo patients endure long-term physical depigmentation and psychological challenges, underscoring the trial's significance in providing a novel therapeutic option with improved safety.
- Founded by former leaders from Pfizer, MSD, and Johnson & Johnson, Lynk Pharmaceuticals is advancing LNK01004 for chronic hand eczema and other inflammatory skin diseases, expanding its dermatology pipeline.
31 Articles
31 Articles
Bennington Banner
Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial of LNK01004 Ointment for Vitiligo
HANGZHOU, China, SHANGHAI and BOSTON, July 8, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that the first patient was successfully dosed on June 30…
Lynk Pharmaceuticals doses first patient in vitiligo drug trial
HANGZHOU, China, SHANGHAI and BOSTON, July 9, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that the first patient was successfully dosed on June 30 in the Phase II clinical trial evaluating its internally developed innovative drug candidate, LNK01004 ointment, for the treatment of vitiligo. This miles…
Coverage Details
Bias Distribution
- 65% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
